Insulet Corporation's CEO and two directors made significant insider stock purchases in 2026, even as the company faced a voluntary medical device correction for certain Omnipod pods. CEO Ashley McEvoy bought 4,300 shares in late February at an average price of $239.35, investing just over $1 million, while independent director Michael Minogue purchased 2,030 shares at $246.23, totaling about $499,800. Independent chair Elizabeth Weatherman bought roughly $497,000 worth of stock in early June at $144 per share, boosting her holdings by 66%. The company initiated a voluntary correction on May 26 for specific lots of Omnipod 5, Dash, and Eros pods due to a cannula tear that could cause insulin under-delivery, sending shares down over 5% to around $146. Insulet shares closed at $161.28 on August 12, down 11.78% over one month and 54.06% over 52 weeks, with a market capitalization of $11.17 billion.
Advanced Micro Devices Inc
Alphabet Inc Class CInsulet CorporationVoluntary correction for Omnipod pods due to cannula tear causing insulin under-delivery.
Intel Corporation